Skip to content
Adrienne Monson – Lifestyle
Author:
Oak Hill Bio
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
July 28, 2026
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
July 27, 2026
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
June 1, 2026